Twice-a-Year Injection Gives Women Full Protection Against HIV, Trial Finds
Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show.
In announcing the findings, Gilead Sciences Inc. said its HIV medication lenacapavir demonstrated 100% efficacy as a preventive treatment.
This is the first round of data generated from Gilead’s PURPOSE program, a collection of five HIV prevention trials that are being conducted around the world, the company noted.
Source: Advances and More licensed by HealthDay
